Background. Cytomegalovirus (CMV) is a late-stage opportunistic infection in people living with human immunodeficiency virus (HIV)/AIDS. Lack of ophthalmological diagnostic skills, lack of convenient CMV treatment, and increasing access to antiretroviral therapy have all contributed to an assumption that CMV retinitis is no longer a concern in low-and middle-income settings.
earlier initiation of antiretroviral therapy (ART) [7] . In contrast, in resource-limited settings, ART is less widely available, people continue to present late in their disease progression [8] , and access to ophthalmologic services is limited [9] . Reported prevalence of CMV retinitis in PLHIV in resource-limited settings is variable, ranging from <5% in Southern Africa [10] to over 30% in Southeast Asia [11] . The lack of an overall epidemiological picture, limited ophthalmological diagnostic skills or convenient CMV treatment in most settings where ART is provided, increasing provision of ART in middle-and low-income countries over the last decade, and the experience in highincome countries that CMV retinitis virtually disappeared with the introduction of ART have all contributed to an assumption that CMV retinitis is generally no longer a concern in low-and middle-income settings [11] .
We conducted this systematic review to gain a better understanding of the prevalence and clinical impact of CMV retinitis in low-and middle-income settings, and how these factors may have changed over the last decade. The review focuses on CMV retinitis because it is typically the only clinical feature of CMV disease that is diagnosed or treated in resource-limited settings.
METHODS

Search Strategy and Selection Criteria
In consultation with clinical experts (D.H., P.S.), we developed a search protocol (Supplementary Appendix 1) to identify studies that reported prevalence of CMV retinitis among PLHIV in low-and middle-income settings. Three databases (PubMed, Embase, and Lilacs) and 3 conferences (Conferences of the International AIDS Society, Conferences on Retroviruses and Opportunistic Infections, and the Annual Meeting of the American Academy of Ophthalmology) were searched for relevant studies published between January 1996 (when triple combination ART first became available) and 1 April 2013. Titles were screened by 1 reviewer (N.F.), and inclusions were verified by a second reviewer (Z.S.). Decisions on final inclusions were made by consensus. Bibliographies of included studies and review articles were hand-searched for potentially eligible studies. Two major HIV treatment providers known to have conducted retinal screening programs (Médicins Sans Frontières and Medical Action Myanmar) were also contacted for unpublished data. No language restriction was applied.
Studies were included if they assessed the occurrence of CMV retinitis by funduscopic examination within a cohort of at least 10 HIV-positive adult patients in low-and middle-income countries, as defined by the World Bank classification [12] . Serological studies and studies diagnosing CMV using polymerase chain reaction (PCR) were excluded, as antibody positivity is consistently high among PLHIV in resource-limited settings [13] and the clinical predictability or correlation of PCR viremia with CMV retinitis, particularly at lower levels, is not well defined [14] .
Data Extraction
Data were extracted by 2 reviewers (N.F., Z.S.) to assess the proportion of HIV-positive individuals diagnosed with CMV retinitis irrespective of clinical disease stage or ART status but where possible CD4 count at diagnosis was extracted. We also sought information on the proportion of patients who had unilateral or bilateral vision loss due to CMV retinitis according to definitions used by the studies (cases of retinal detachment were considered as cases of blindness because of the complexity of treatment), other organ disease, and mortality among patients with CMV retinitis. We also extracted information on patient and program characteristics, diagnostic approach, definition of CMV retinitis, and indicators of study quality according to a predefined quality scoring table.
Data Analysis
Point estimates and 95% confidence intervals were derived for all outcomes. For prevalence estimates, proportions were stabilized through arcsine square-root transformation [15] and pooled using a DerSimonian-Laird random-effects model [16] . Betweenstudy heterogeneity was estimated using the τ 2 statistic [17] . Prespecified subgroup analyses were carried out to assess the difference in prevalence according to geographical location, clinic setting ( primary care center vs hospital), study design, study period, ART use, and patient selection (eg, if patients were selected for screening either by clinical/immunological criteria or after referral following preliminary eye examination). All analyses were conducted using Stata software, version 12 (StataCorp, College Station, Texas), with a P value <.05 considered to be statistically significant.
RESULTS
Study Characteristics
Of 1702 articles and 397 conference abstracts screened, 53 met our inclusion criteria and were taken through for review, comprising 39 published articles and 13 conference abstracts. The full list of inclusions is provided in Supplementary Appendix 2. Data from 13 unpublished cohorts were also included ( Figure 1 Table 1 . The methodological quality of the studies overall was considered to be low to moderate (Supplementary Table 1 ). The majority of studies (52) were prospective in design and reported using indirect ophthalmoscopy with pupillary dilation (42 studies), and 30 studies reported that screening was carried out by an ophthalmologist; however, less than half of studies (30) reported outcomes stratified by CD4 count, and only 5 studies verified eye assessments with a second examiner (1 using retinal photography). Most studies undertook funduscopic examination on patients who were selected using clinical/immunological criteria or referred following preliminary eye examination elsewhere (44 studies).
Prevalence and Clinical Characteristics of CMV Retinitis
Overall, there was substantial heterogeneity between studies (τ 2 = 0.09), with prevalence for CMV retinitis ranging from Figure 2 ). Nineteen studies reported whether CMV retinitis affected 1 or both eyes, and the raw proportion of bilateral cases of CMV retinitis was 42.9% (95% CI, 38.9%-47.0%). 28 studies reported CMV retinitis cases stratified by CD4 count. Among these, after excluding 8 studies that selected patients using immunological criteria (eg, only considering patients with a CD4 count of <100 cells/µL), CD4 count at diagnosis of CMV retinitis was <50 cells/µL in 73.4% of cases, 50-100 cells/µL in 15.6% of cases, 100-200 cells/µL in 8.3% of cases, and >200 cells/µL in Twenty-five studies provided sufficient information to estimate the proportion of cases of CMV retinitis that resulted in some degree of vision loss: this ranged from 0% [18, 19] to 75% [20] , with an overall raw proportion of 31.6% (27.6%-35.8%). In over a quarter of cases (27.6% [95% CI, 20.9%-35.1%]) vision loss was bilateral.
Mortality was reported by 8 studies, with data disaggregated by CMV status in 5 studies. Overall, 22% of patients with CMV retinitis were known to have died, but none of these studies provided autopsy data on cause of death or time of death in relation to diagnosis of CMV retinitis.
DISCUSSION
The prevalence of CMV retinitis in high-income settings has declined significantly over the last 15 years as ART has become more widely available and the immune status of patients at ART initiation has progressively improved [21] . In contrast, this review found that the prevalence of CMV retinitis in resource-limited settings, notably Asian countries, remains high. Part of the explanation for the enduring high prevalence of CMV retinitis in Asia can be found in the fact that, despite considerable progress in scaling up access to ART, the proportion of patients who present late for HIV care remains high, with around 1 in 5 patients presenting with a CD4 count of <100 cells/µL [22] , and median CD4 at ART initiation appears to be lower in Asian settings compared to African settings [23] .
This review indicates an important clinical burden of CMV retinitis, predominantly in patients with a CD4 count of <100 cells/µL, and suggests that the disease is commonly bilateral and commonly associated with vision loss. The proportion of individuals with CMV retinitis who have bilateral involvement and the proportion who have CD4 counts >50 cells/µL suggests that infection is being diagnosed after a substantial period of delay from the initial development of retinal lesions. Studies from the United States found that CMV retinitis was bilateral in only 28% of newly diagnosed cases in the era before use of ART, and in only 26% of newly diagnosed cases after the introduction of ART. Furthermore, among the latter group, involvement was only 9% among ART-naive patients, suggesting that second eye involvement is a late occurrence in the course of CMV retinitis [24] . In the same study, approximately 20% of patients with newly diagnosed CMV retinitis had CD4 counts >50 cells/µL, but nearly all of those individuals had just started ART or had evidence of ART failure. Active CMV retinitis can be seen in the early stages of ART, before immune recovery is achieved [24] . That over a quarter of individuals with CMV retinitis in this review had CD4 counts >50 cells/µL likely reflect diagnoses made after CD4 counts begin to rise with the start of ART. Taken together, these observations suggest missed opportunities for earlier diagnoses of CMV retinitis, with the potential for preservation of vision.
Consistent with expectations, prevalence was higher in programs that selected patients at higher risk (ie, those presenting with low baseline CD4 count and/or AIDS-defining illness), underscoring the importance of routine funduscopic examination for "late presenters." This review also confirms prior reports that prevalence of CMV retinitis is generally higher in Asia than in Africa [10, 11] ; this finding is despite a high rate of prior exposure to CMV [25] and presence of end-organ CMV disease in autopsy studies in PLHIV in sub-Saharan Africa [26] . Explanations put forward for this difference include virus or host genetic differences [27] and competing mortality risks [28] . Antiretroviral coverage is, on average, lower in Southeast Asia compared to Africa (39% vs 49%) [29] . Nevertheless, the higher HIV prevalence in sub-Saharan Africa means that the absolute number of CMV cases may also be high.
Very little information was reported regarding extraocular CMV disease. Diagnosis of CMV retinitis can be established on physical examination, but diagnosis of other forms of endorgan CMV disease such as esophagitis, hepatitis, colitis, and pneumonia requires confirmation by biopsy, fulfillment of specific histopathologic and virologic criteria, and exclusion of other diseases, all of which are challenging in resource-limited settings. A large multicenter prospective cohort study from Europe reported that among 707 patients with documented end-organ CMV disease, 64% had CMV retinitis, 27% had extraocular CMV disease, and 8% had both [6] . Autopsy studies from high-income settings in the pre-ART era found disseminated CMV infection in up to 60% of patients [3, 4] , and CMV pneumonitis has been identified among the main pathological findings in up to 50% of deaths among people living with HIV and having pulmonary infections in sub-Saharan Africa [26] . Moreover, the presence of CMV retinitis predicts mortality [30] , systemic anti-CMV treatment reduces mortality in patients with CMV retinitis [31] , and high CMV viremia has been found to be independently associated with a higher risk of mortality in both Asian [32] and African [33] settings.
We used a broad search strategy that was able to include a large number of published and unpublished reports from a wide range of countries and program settings. By definition, publication bias exists in HIV treatment programs as the majority of treatment programs in low-income settings do not present or publish details on their cohorts. To compensate for this, we applied a random-effects analysis and present it with uncertainty intervals. The included studies should therefore be interpreted as a sample of all possible cohorts. We undertook subgroup analyses to explain some of the variation in prevalence. These analyses were limited to covariates reported by the studies, but other explanations may exist. The majority of programs undertook eye examinations using the commonly accepted "gold standard" for diagnosis of CMV retinitis, which is dilated examination of the entire retina with an indirect ophthalmoscope by a trained clinician. Although this provides confidence in the data, it limits the generalizability of the findings as patients presenting to centers that are able to do funduscopy are not representative of the broader patient population. Patients included in this review were mostly severely immunocompromised, and some had been referred for ophthalmologic examination, and the results should be interpreted in this light. Another important limitation was that reporting of important covariates was inconsistent, with few studies reporting nadir CD4 count, timing of ART initiation and associated complications, extent of vision loss, type and outcomes of treatment provided, cause of mortality, and extraocular CMV disease. Our inclusion criteria resulted in a few studies being included from the pre-ART era. We explored the potential influence of these studies in a sensitivity analysis that removed all studies reporting data prior to 2000; this did not significantly change the regional prevalence estimates. There was also a lack of highquality studies, in particular longitudinal studies with adequate follow-up. Information about duration of disease is lacking, especially as it relates to vision loss, and reports of CMV retinitis early in the course of disease will lead to underestimates of vision loss as, in general, CMV progresses slowly but without treatment will invariably result in blindness. Finally, underdiagnosis of CMV retinitis may result from the fact that approximately 20% of patients who first present for HIV care in resource-limited settings are lost to follow-up within a year of starting ART [34] , and around half of these individuals will have died [35] . Although many of these patients will have received ART, CMV retinitis can still develop after start of ART, during the first 3-to 6-month period before immune recovery occurs [24] .
Our review has several potential implications for policy and practice. We found no difference in the proportion of patients identified with CMV retinitis when screening was done by trained HIV clinicians compared to ophthalmologists. From an operational perspective this is encouraging and points toward the potential for integrating routine retinal examination as part of basic care for all late presenters, especially those with CD4 <100 cells/µL, which may also allow for the diagnosis of other HIV-related conditions such as disseminated tuberculosis [36] . The fact that our review found a high prevalence of CMV retinitis in some primary care settings underscores the value of such capacity building.
This review highlights the need for improved detection of patients infected with CMV retinitis and clearly defined, standardized diagnostic criteria that can be applied easily in areas where experience with CMV retinitis has been limited. CMV retinitis is a disease mainly occurring among people who are severely immunocompromised. Recent studies have shown that with effective ART, even people starting ART with a very low CD4 cell count can expect to live several decades [37] , but quality of life will be severely compromised by loss of vision. Routine retinal screening by indirect ophthalmoscopy of all late presenters with CD4 <100 cells/µL should be considered. There is also a need to define optimal screening approaches to identify patients who would benefit from systemic treatment for extraocular CMV disease. Consideration should also be given to oral systemic prophylaxis in high-risk patients with HIV, as this approach was demonstrated to halve end-organ disease in HIV patients in the pre-ART era [38] , may protect against posterior pole disease [24] , and is a widely accepted method to reduce CMV disease and associated mortality in patients undergoing solid organ transplant [39] . Future research is encouraged to further document the burden of CMV disease in resourcelimited settings, define simple approaches to introducing eye examination as part of the basic care package for patients presenting late for ART care, and assess the feasibility of treating CMV retinitis in nonspecialized settings.
Given that CMV is a systemic infection and a potential cause of a spectrum of morbidity and mortality, improving access to oral systemic treatment with valganciclovir is a priority: access to oral therapy particularly needs to improve in resource-limited settings where lack of specialists limits capacity to administer intraocular injections. In addition, the cost of CMV treatment in developing countries is currently too expensive in high-burden settings, and where it is provided represents a substantial part of overall treatment costs for PLHIV [40] . Improving access to convenient oral therapy would stimulate HIV programs to introduce retinal screening-an incentive that has been missing for the last 20 years in resource-limited settings due to the lack of any convenient and affordable treatment option. To date, the demand for valganciclovir to treat CMV has been very limited, which has provided insufficient incentive for manufacturers to develop quality-assured and affordable treatment for CMV infections.
Finally, the enduring burden of CMV retinitis and associated vision loss points to an urgent need to improve and sustain efforts to identify people who are HIV-positive, ensuring that they are enrolled into care earlier in their disease progression. At the same time, national HIV programs should ensure capacity to manage late presenters, including early diagnosis and treatment of CMV retinitis where prevalence is high, to reduce the risk of blindness and, potentially, other CMV-related morbidity and CMV-associated mortality.
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